[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"David Palma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,74,103,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633300","phase-2-staph-nasal-decolonization-to-improve-function-and-feeding-100633300",false,"NCT07524894","Staph Nasal Decolonization to Improve Function and Feeding","Staph Nasal Decolonization to Improve Function and Feeding: A Randomized Clinical Trial (SNIFF)","SNIFF","Inclusion Criteria:\n\n* Histologically confirmed mucosal squamous cell carcinoma of the head and neck, planned to receive a dose equivalent to 60 Gy in 30 fractions or higher, with or without concurrent systemic treatment. This can include hypofractionated regimens of 55 Gy in 20 fractions. Primary sites considered: oral cavity, oropharynx, larynx (excluding T1-T2N0 glottic cancers), hypopharynx. The radiotherapy treatment planned can be definitive or adjuvant.\n* Age ≥18 years.\n* ECOG performance status 0-2\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Mupirocin allergy\n* Skin or salivary gland malignancy\n* Early stage glottic cancers (T1-2N0)","ALL","18 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Radiation therapy is a type of treatment that involves using radiation beams targeted at a cancer to destroy the cancer cells or slow their growth. This type of treatment has helped many cancer patients for decades and is intended to kill cancer cells directly. Patients with head and neck cancer are commonly treated with radiation, sometimes after surgery and sometimes the radiation is delivered with chemotherapy at the same time. Radiation treatments have side effects, and the treating oncologist works with each patient to determine the best treatment and manage the side effects.\n\nIt has been shown that one of these side effects of radiation is irritation or \"sunburn\" of the lining of the mouth and throat (radiation mucositis), which can cause difficult or painful swallowing, and pain\u002Fdiscomfort in the mouth\u002Fthroat. These side effects can lead to dehydration, and weight loss, and sometimes can lead to hospital admissions and treatment delays. This is usually treated by the prescription of pain relievers, dietician support and, if necessary, nutrition via a tube (G-tube).\n\nBecause of these symptoms involving the mouth and throat, researchers are looking to study the effect of a common ointment antibiotic used to reduce an infection known as Staphylococcus Aureus. The infection is commonly located in the front of the nose, and during treatment this infection can travel from the nose to the throat and worsen the radiation mucositis and the pain it causes. The study will measure if a course of ointment antibiotic in the nose (twice per day, 5 days on, 5 days off, repeated) can reduce your pain during treatment by reducing severe mucositis related to Staphylococcal infection. This study compares the effects of the study treatment with a \"placebo,\" which looks the same but does not contain any active medicine. Neither you nor your doctor will know which one you are receiving until the study ends. The antibiotic used in the study arm is being used \"off-label\" for intranasal application (it is normally used to treat skin infections). Possible side effects include local skin irritation or allergic reactions, and in rare cases, a severe allergic response (anaphylaxis).",[27,28,29],"Radiation Mucositis","Staphylococcal Aureus Infection","Head and Neck Cancer","NOT_YET_RECRUITING","2026-04-27",{"date":33,"type":34},"2026-05-01","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2028-01-30",{"name":40,"class":41},"David Palma","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100515039","phase-2-reducing-respiratory-symptoms-of-pulmonary-irradiation-in-interstitial-lung-disease-100515039","NCT05986318","Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease","Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease: A 2x2 Factorial Randomized Phase II Trial Testing N-Acetyl Cysteine and Dexamethasone","RESPIRE-ILD","Inclusion Criteria:\n\n* Lung cancer or 1-2 oligometastatic pulmonary lesions planned for radical intent radiotherapy \\[minimal Biologically Effective Does (BED) of 48 Gy10 (Gray) or biological equivalent\\].\n* Pathologically (histologically or cytologically) proven diagnosis of cancer is not required, but strongly recommended.\n\n  * If the risk of biopsy is unacceptable, pathologic confirmation is not required providing there is growth over time on Computed Tomography (CT) imaging and\u002For Fluorodeoxyglucose (FDG) avidity that is strongly suggestive of malignancy.\n* Fibrotic Interstitial Lung Disease (ILD) of any subtype, as diagnosed by a respirologist and confirmed by central review\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n* Age ≥ 18\n* Life expectancy \\> 6 months\n* Patients are allowed to receive anti-fibrotic agents used in the treatment of Idiopathic Pulmonary Fibrosis (IPF) or non-IPF fibrotic ILD (e.g. nintedanib, pirfenidone) and\u002For corticosteroids, if those are part of their current ILD treatment regimen. Other immunosuppressive drugs such as mycophenolate, azathioprine, cyclophosphamide, and rituximab must be stopped for 2 weeks prior and 2 weeks after Radiation Therapy (RT).\n* Concurrent standard chemotherapy is allowed where indicated. All other systemic therapies, including biologic targeted agents or immunotherapy, or any drugs with known radiosensitive effects, must be stopped for 2 weeks prior and 2 weeks after treatment.\n\nExclusion Criteria:\n\n* Prior lung radiotherapy\n* Current use of oral or intravenous corticosteroids\n* Plans for the patient to receive other local therapy to the target lesion(s) while on this study, except at disease progression\n* Any medical condition that could, in the opinion of the investigator, preclude radiotherapy or prevent follow-up after radiotherapy\n* Pregnancy\n\n  * If not pregnant, use of effective contraception methods for women of childbearing age is required which can include:\n\n    * hormonal methods (e.g. oral, injected, implanted),\n    * placement of an intrauterine device,\n    * barrier methods (i.e. condoms),\n    * sterilization of the partner (e.g. previous vasectomy)\n    * abstinence\n  * Women who become pregnant should stop taking NAC and\u002For dexamethasone and inform their study doctor.\n  * Male participants should use adequate forms of birth control with their partners.\n* Currently breastfeeding\n* Current or recent use of NAC\n* Contraindications to dexamethasone or N-Acetyl Cysteine (NAC). These include:\n\n  * Previous intolerance or allergy to dexamethasone or NAC\n  * Scleroderma\n  * Active infection\n  * Glaucoma\n  * Psychiatric disorder that could be exacerbated by dexamethasone\n  * Cystinuria\n  * Any other condition that the treating physician believes to be a contraindication to dexamethasone or NAC",{"count":52,"type":21},98,[24],"In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.",[56,57],"Lung Cancer","Interstitial Lung Disease",[59,60,61,62,63],"Pulmonary Irradiation","Radiation Therapy","N-Acetyl Cysteine","Dexamethasone","Radiation Pneumonitis","RECRUITING","2026-03-06",{"date":67,"type":34},"2026-03-09",{"date":69,"type":34},"2025-01-07",{"date":71,"type":21},"2032-12-31",{"name":40,"class":41},3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":42},"100618864","stereotactic-post-operative-radiotherapy-for-intraparotid-metastatic-cutaneous-squamous-cell-carcinoma-100618864","NCT07337161","Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma","SPRINT","Inclusion criteria\n\n* Age ≥ 18 years\n* Patient able to provide informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Patient is a candidate for curative intent treatment\n* Patient is able to comprehend English adequately to complete patient reported outcome questionnaires\n* Biopsy-confirmed cutaneous SCC\n* Definitive resection of a primary cutaneous tumor within the head and neck\n* Tumor stage T1-T4 (AJCC 8th edition); or tumor stage unknown (T0\u002FTx) with a positive intraparotid, peri-parotid or cervical node that is assumed to be from a head and neck cutaneous SCC by the treating oncologist\n* Nodal stage N1-N3 (AJCC 8th edition)\n* At least 1 indication for adjuvant radiation, including:\n\n  * T3 or T4 tumor stage\n  * Lymphovascular invasion (LVI)\n  * Perineural invasion (PNI)\n  * Positive or close (≤ 3 mm) margin\n  * ≥ 1 positive intraparotid, peri-parotid or cervical lymph node\n  * Multiple local recurrences or multi-focal disease\n* Neoadjuvant or adjuvant immunotherapy is allowed\n\nExclusion criteria\n\n* Definite metastatic disease at diagnosis\n* Pregnant or breastfeeding women\n* Significant health conditions or contraindications to receiving surgery and radiation\n* History of previous head and neck cancer within 5 years, except for localized skin cancers (i.e. no nodal or distant spread)\n* Prior head and neck radiation involving the ipsilateral parotid or neck. However, prior radiation to the index skin cancer that has led to the parotid nodal disease being treated on this trial is allowed, as long as there is no overlap, or inconsequential overlap, in the judgement of the treating oncologist.\n* Indications for contralateral neck radiation (i.e. contralateral or bilateral lymph nodes)\n* Previous invasive malignancy within 5 years, unless controlled with no evidence of disease",{"count":82,"type":21},90,[84],"NA","The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the head and neck after surgical resection.\n\nStereotactic radiotherapy works in the same way that conventional (standard) radiotherapy does to kill cancer cells by damaging their genetic material and stopping the cancer cells from making copies of themselves.\n\nThis study will help the study doctors find out if this different approach is the same, better, or worse than the standard of care for your cancer.",[87,88],"Cutaneous","Head and Neck Cancer Squamous Cell Carcinoma",[90,91,92,93,94],"skin","head and neck","radiation","SBRT","SABR","2026-01-06",{"date":97,"type":34},"2026-01-13",{"date":99,"type":34},"2025-10-21",{"date":101,"type":21},"2035-09-01",{"name":40,"class":41},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":5},"100494360","phase-3-a-randomized-phase-iii-trial-of-stereotactic-ablative-radiotherapy-for-patients-with-up-to-10-oligometastases-and-a-synchronous-primary-tumor-100494360","NCT05717166","A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.","SABR-SYNC","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing to provide informed consent\n* Karnofsky performance status \\> 60\n* Life expectancy \\> 6 months\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Total number of metastases 1-10 at the time of enrollment, with a primary tumor also present\n* Restaging completed within 12 weeks prior to randomization (see section 5.1)\n* For patients receiving thoracic radiotherapy, the enrolling physician must confirm there are no computed tomography (CT) changes suggestive of fibrotic interstitial lung disease (ILD) (i.e. reticular changes, traction bronchiectasis, or honeycombing) reported on any prior CT scans. If any are present, the patient must be assessed by a respirologist to rule out ILD prior to enrollment.\n* 10 or fewer lifetime metastases from the cancer for which participants are being enrolled\n\nExclusion Criteria:\n\n* Serious medical comorbidities precluding radiotherapy. These include ILD in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI) tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C); please see the Child-Pugh score calculator.\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. All such cases must be discussed with a member of the study steering committee.\n* Malignant pleural effusion\n* Inability to treat all sites of disease\n* Brain metastasis \\> 3 cm in size or a total volume of brain metastases greater than 30 cc.\n* Metastasis in the brainstem\n* Clinical or radiologic evidence of spinal cord compression\n* Metastatic disease that invades any of the following: GI tract (including esophagus, stomach, small or large bowel), or skin\n* Pregnant or lactating women",{"count":111,"type":21},180,[113],"PHASE3","This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease.\n\nPatients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).",[116],"Metastatic Tumor","2025-12-24",{"date":119,"type":34},"2025-12-31",{"date":121,"type":34},"2023-10-06",{"date":123,"type":21},"2029-04",{"name":40,"class":41},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100528133","is-radiation-before-pathology-a-feasible-approach-in-the-palliative-oncology-setting-a-pragmatic-clinical-trial-100528133","NCT06156800","Is Radiation-before-pathology a Feasible Approach in the Palliative Oncology Setting? A Pragmatic Clinical Trial","Is Radiation-before-pathology a Feasible Approach in the Palliative Oncology Setting? A Pragmatic Clinical Trial (RT-NOW)","RT-NOW","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing to provide informed consent\n* Palliative treatment intent: either metastatic or incurable locally advanced disease\n* Tissue diagnosis is not required for determination of dose\u002Ffractionation scheme\n* Recent cross-sectional imaging \\[for example - Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT)\\] of the area to be treated, done within the past 3 months\n* Treating physician considers the pre-test probability of cancer greater than 95 percent based on clinical judgement and radiological findings.\n* The patient has at least 1 site of cancer amenable to biopsy\n\n  * As per standard practices, if the radiation oncologist will be radiating the only site available to biopsy, they should proceed with caution. Participants should only be enrolled on trial if the risk of harm from delaying Radiation Therapy (RT) significantly outweighs the risks of possible non-diagnostic tissue. If the participant may potentially be eligible for systemic therapy, the treating radiation oncologist should consult a medical oncologist for an opinion regarding the risks of non-diagnostic molecular testing. The weighing of these priorities should be thoroughly discussed with the participant and the discussion should be documented.\n  * Reasons for radiating a participant with a single lesion prior to biopsy include:\n\n    * Spinal cord compression (actual or impending) and inoperable\n    * Brain metastasis with significant symptoms or neurologic deficits and inoperable\n    * Other lesions causing neurologic deficit\n    * Pulmonary lesion causing or threatening lung obstruction\n    * Uncontrolled bleeding (including hemoptysis and hematuria)\n    * Superior vena cava obstruction (actual or impending)\n    * Limited upside to molecular testing, as determined by the medical oncologist (for example - participant unfit for available systemic therapies, limited options for systemic therapy)\n* Radiation is considered urgent (for example - participant should receive radiation prior to biopsy date) o Urgent indications may include but are not limited to the reasons listed previously, as well as the following:\n\n  * Painful metastases or primary lesion not adequately responding to analgesia\n  * Symptomatic brain metastases\n  * Bleeding\n  * Impending pathologic fracture\n\nExclusion Criteria:\n\n* Participant is potentially eligible for curative treatment\n* Clinical suspicion of lymphoma o Some features may be suggestive of lymphoma, including fever or night sweats (for example - B symptoms excluding weight loss), or imaging showing well-defined, homogenous lymphadenopathy. These findings are not exclusion criteria specifically, but should be considered by the clinician in formulating their differential diagnosis.",{"count":134,"type":21},48,"OBSERVATIONAL","When a doctor suspects cancer, often a biopsy is taken for testing to confirm if cancer is present. Usually, doctors would wait for the results of a biopsy before delivering radiation, but this may lead to a patient having to wait for a treatment that he or she urgently needs.\n\nWith long wait times for biopsies in Canada, this may lead to symptoms and risks of complications from cancer in the meantime. Therefore, this study is being done to answer the following question: Is it safe and feasible to deliver radiation before obtaining a biopsy in a carefully selected group of patients who urgently need radiation treatment.",[138],"Cancer",[140,141,60,142],"Palliative Irradiation","Biopsy","Pathology","2025-07-22",{"date":145,"type":34},"2025-07-25",{"date":147,"type":34},"2024-04-19",{"date":149,"type":21},"2027-07-01",{"name":40,"class":41},""]